You are here

SARC003

Completed
Phase 2 study of sequential gemcitabine followed by docetaxel for recurrent Ewing’s sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma
Type of Sarcoma: 
Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma
Drug: 
Gemcitabine and Docetaxel
Accrual Status: 
Closed
Co-Principal Investigators: 

Elizabeth Fox, MD
National Cancer Institute
 
Shreyaskumar Patel, MD
MD Anderson Cancer Center

For more information about this trial and open sites: